MET and neoplasm: Subsequently, population PK and MET phosphorylation results derived from paired tumor biopsies acquired in the first-in-human (FIH) trial were integrated into the translational model and indicated that ≥95% target inhibition is achieved in >90% of patients with the standard dose of 500 mg (43), and in >80% of patients with a reduced dose of 250 mg (59).